MedTrace Logo

Evaluating the Efficacy of Artificial Intelligence-based Computer Aided Diagnosis Software That Assists in Determining Whether or Not to Conduct Amyloid PET for the Diagnosis of Alzheimer's Disease by Predicting Amyloid PET Positivity in Mild Cognitive Impairment Patients

NCT05383053 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 227

Last updated 2022-09-16

No results posted yet for this study

Summary

* Purpose of clinical trial; This clinical trial is designed to evaluate the effectiveness of 'NeuroAI' prediction accuracy compared to the amyloid PET test results by retrospectively collecting medical data of patients with mild cognitive impairment to evaluate the effectiveness of artificial intelligence-based brain image detection and diagnosis assistance software 'NeuroAI'.
* Participants; Patient with mild cognitive impairment

Conditions

Interventions

DEVICE

NeuroAI

NeuroAI is an artificial brain diagnostic software that determines whether to perform amyloid PET tests for Alzheimer's by specialists through the detection of amyloid PET positive rates based on brain MR images (T1 weighted MRI, T2 FLAIR MRI) and clinical information (age, gender, and APOE) genotype. When using this product, input gender, birth year, and apolipoproteinE (APOE) genotype and upload T1 MR image and T2 Flair image, input data and image analysis result data are integrated to infer the positive rate of amyloid PET by PET positive prediction model. The result report provides image analysis results and amyloid PET positive prediction results compared to normal groups.

Sponsors & Collaborators

  • Chonnam National University Hospital

    collaborator OTHER

  • Chosun University Hospital

    collaborator OTHER

  • Neurozen Inc.

    lead INDUSTRY

Principal Investigators

  • Byeong Chae Kim, MD · Professor (Department of Neurology,Chonnam National University Hospital)

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-22
Primary Completion
2022-08-10
Completion
2022-09-08

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05383053 on ClinicalTrials.gov